Abstract
A Phase II trial of TCN-P was conducted in metastatic or recurrent squamous cell carcinoma of the cervix using a 5-day continuous infusion schedule. The starting dose was 35 mg/m2 x 5 days and courses were repeated every 6 weeks. Among 21 evaluable patients, 2 responses were observed. One patient had a complete response for 19+ months. Another patient had a partial response for 5+ months, but developed symptomatic hypocalcemia, requiring discontinuation of the drug. Using this dose and schedule TCN-P appears to have limited activity in metastatic or recurrent squamous cell cancer of the cervix.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 506-508 |
| Number of pages | 3 |
| Journal | American Journal of Clinical Oncology: Cancer Clinical Trials |
| Volume | 16 |
| Issue number | 6 |
| DOIs | |
| State | Published - 1993 |
| Externally published | Yes |
ASJC Scopus subject areas
- Oncology
- Cancer Research